Clinical Trial Update: Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating larotinib for unresectable advanced or recurrent esophageal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Larotinib (larotinib)

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Esophageal Cancer | Phase 3 | Status: RECRUITING